cetpinhibition.org

HDL biologyLandmark

Two independent inhibitors reveal separate CETP binding sites for cholesteryl ester and triglyceride transfer, uncoupled in vivo (J Biol Chem 1995)

Original title: Evidence that cynomolgus monkey cholesteryl ester transfer protein has two neutral lipid binding sites

J Biol Chem · · 9

Melchior GW, Greenlee KA, Castle CK, Prough MJ, Milne RW, Marotti KR, Kezdy FJ

Two inhibitors of cynomolgus monkey CETP were evaluated: a monoclonal antibody against purified CETP, and 6-chloromecuric cholesterol. The antibody severely inhibited triglyceride transfer but had variable effects on cholesteryl ester transfer, while Fab fragments blocked triglyceride transfer completely but had no effect on cholesteryl ester transfer. In contrast, 6-chloromecuric cholesterol severely inhibited cholesteryl ester transfer with minimal effect on triglyceride transfer. Combining both inhibitors blocked both transfer types, indicating they act at different binding sites. Given subcutaneously to monkeys at a dose inhibiting plasma triglyceride transfer by more than 90%, the antibody had no detectable effect on HDL cholesterol but reduced HDL triglyceride from 13 +/- 2 to 1 +/- 0 mol/mol of HDL, confirming that cholesteryl ester and triglyceride transfer were uncoupled in vivo.

Read the paper (DOI)PubMed

Original abstract

Two inhibitors of cynomolgus monkey cholesteryl ester transfer protein were evaluated. One, a monoclonal antibody made against purified cynomolgus monkey cholesteryl ester transfer protein, was capable of severely inhibiting triglyceride transfer, but had a variable effect on cholesteryl ester transfer. At low antibody to antigen ratios, there was what appeared to be a stoichiometric inhibition of cholesteryl ester transfer, but at high antibody to antigen ratios the inhibition of cholesteryl ester transfer was completely relieved, even though triglyceride transfer remained blocked. Fab fragments of the antibody had no effect whatsoever on cholesteryl ester transfer, but were capable of completely blocking triglyceride transfer. The other inhibitor, 6-chloromecuric cholesterol, severely inhibited cholesteryl ester transfer with minimal inhibition of triglyceride transfer. When both inhibitors were added to the assay, both cholesteryl ester and triglyceride transfer were inhibited; an indication that the inhibitors did not compete for the same binding site on cholesteryl ester transfer protein. When the antibody was given subcutaneously to cynomolgus monkeys at a dose which inhibited triglyceride transfer in the plasma by more than 90%, there was no detectable effect on the high density lipoprotein (HDL) cholesterol level, but the HDL triglyceride levels decreased from 13 +/- 2 to 1 +/- 0 mol/mol of HDL (mean +/- S.D.); an indication that the antibody uncoupled cholesteryl ester and triglyceride transfer in vivo. The 6-chloromecuric cholesterol could not be evaluated in vivo because it is a potent lecithin:cholesterol acyltransferase inhibitor. The fact that cholesteryl ester transfer can be inhibited without effect on triglyceride transfer and, conversely, that triglyceride transfer can be inhibited without effect on cholesteryl ester transfer indicates that these two lipids are not transferred by a single, non-discriminatory process.

HDL biologymechanisms

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.